Both low-level mupirocin resistance (LMR) and high-level mupirocin resistance (HMR) have been identified. The aim of this study was to determine the epidemiology of LMR and HMR in MRSA isolates at five hospitals that have used mupirocin for targeted decolonization as part of successful institutional control programmes.
Introduction
Mupirocin (pseudomonic acid A) is an antibiotic commonly used for the nasal decolonization of MRSA and MSSA. 1, 2 It has been widely used as part of the successful UK MRSA control programme over the last 10 years. 3 It has also been shown to reduce the rate of MRSA body site infections when applied universally in conjunction with chlorhexidine to all patients admitted to the ICU. 4 Mupirocin-resistant Staphylococcus aureus was first reported in 1987 at St Thomas' Hospital, which now forms part of Guy's and St Thomas' NHS Foundation Trust (GSTT). 5 Mupirocin binds to the bacterial isoleucyl-tRNA synthetase gene, inhibiting protein replication. 1, 2 Mupirocin resistance is classified as either low-level mupirocin resistance (LMR) or high-level mupirocin resistance (HMR). 1 LMR is mediated through point mutations in the native isoleucyl-tRNA synthetase gene (ileS) causing a Val-to-Phe change in the mupirocin-binding site, at either residue 588 (V588F) or 631 (V631F). 6 HMR is due to carriage of a distinct plasmid-mediated isoleucyl-tRNA synthetase gene, most commonly mupA, although mupB has been reported. 2, 7, 8 HMR is associated with MRSA decolonization failure; LMR appears to be associated with early recolonization and, in some reports, decolonization failure. The prevalence of mupirocin resistance (LMR and HMR) and of the underpinning genotypic determinants has been widely reported. In 1998, a survey of MRSA from 19 European hospitals found HMR in 3.6% and LMR in 2.6% of 194 MRSA samples. 12 A Japanese cohort reported LMR prevalence of 0.8% -4.0% between 1998 and 2001 with no HMR detected. 13 A more recent study of 156 MRSA isolates in the USA demonstrated LMR in 18.6% and HMR in 5.1% of isolates. 14 Similarly, a Singaporean cohort study identified HMR in 11% of 307 isolates. 15 Several reports suggest that carriage of mupA is more common in some clones, but, to our knowledge, the distribution of LMR by MRSA clone has not been reported. 16 -18 The concern with increasing use of mupirocin is selection of MRSA isolates that are mupirocin resistant, thus compromising the long-term sustainability of decolonization both for the individual patient and as an infection control intervention to prevent transmission. 1, 2 Recent hospital admission and use of mupirocin have been identified as risk factors for HMR or LMR, implying that exposure to an environment where there is intensive mupirocin use is a risk factor for resistance. 19, 20 It is, however, unclear whether there is selection for both HMR and LMR and how this relates to carriage of mupA and the V558F mutation. 1,13,14,21 -23 This study reports the prevalence of mupirocin resistance (LMR and HMR) and carriage of mupirocin resistance determinants (V588F/V631F and mupA/mupB) in hospital and community MRSA isolates identified in three laboratories serving five hospital and community healthcare facilities across three adjacent London boroughs. All healthcare facilities in this area have implemented effective infection control programmes over the past 10 years involving use of mupirocin for decolonization of patients identified in the universal admission screening programme ('screen and treat' approach) 24 and seen MRSA levels fall by .85%. 25 The aim of the study was to determine the distribution, risk factors and clonal variation in LMR and HMR and their genotypic determinants.
Methods
From 1 November 2011 to 29 February 2012, we collected all MRSA isolates identified by a hospital cohort that serves a resident population of 867254 26 and provides microbiology diagnostic services to all inpatients, outpatients and community patients in the London boroughs of Southwark, Lambeth and Lewisham. Participant centres included four acute tertiary hospitals in two NHS trusts (GSTT and King's College Hospital NHS Foundation Trust) and an acute district general hospital (Lewisham and Greenwich NHS Trust). All three NHS trusts had polices in place for use of mupirocin for decolonization of MRSA inpatients, although in one trust (GSTT) it was not used in the ICUs. 27 The number of nasal mupirocin tubes prescribed during the study period was obtained from pharmacy electronic systems at each trust.
MRSA isolates were submitted to the Centre for Clinical Infection and Diagnostics Research at GSTT. Isolates confirmed as MRSA by culture on chromogenic agar (Oxoid Brilliance) and rapid latex agglutination test (Staphaurex, Remel) were included in the study. Anonymized patient-level details were submitted with each specimen and used to construct a database. MRSA isolates were screened for mupirocin resistance using a semiconfluent inoculum 28 on Iso-Sensitest agar with a 200 mg disc (Oxoid), incubated at 35-378C in air for 18 -20 h. NCTC 6571 quality control strain was used for internal validation. HMR was defined by an inhibition zone of ,18 mm based on a BSAC Working Party study conducted at St Thomas' Hospital. This breakpoint coincides with that defined by EUCAST. 1 To define 30 and BLAST. 31 WGS was conducted on the first confirmed MRSA isolate from each individual at each unique healthcare setting (i.e. whenever an individual was admitted as an inpatient to a new hospital or received care in a new outpatient clinic or community service throughout the study period); thus, follow-up genomic information was available for patients who received care at multiple settings.
Isolates carrying mupA or mupB were classified as 'genotypic HMR'. 7, 8 Isolates with V588F or V631F chromosomal mutations in Ile, respectively, were classified as 'genotypic LMR'. 6 Isolates were classified as 'hospital associated' (HA) if they were PVL negative and contained SCCmec types I, II or III and 'community associated' (CA) if they were PVL positive or contained SCCmec types IV, V or non-typeable. 32, 33 Exceptions were ST22-IV and ST5-IV isolates, which were classified as HA unless they were PVL positive.
32,33

Analysis
Univariate logistic regression analyses of the patients' first healthcare episode were used to investigate risk factors for phenotypic HMR and LMR. The patients' first episode was classified as 'inpatient', 'outpatient' or 'community' depending on whether provision of healthcare involved admission to hospital, an outpatient clinic appointment or service from a general practitioner or other community provider, respectively. The first episode was defined as 'HMR' if at least one MRSA isolate during that episode was HMR; an episode was defined as 'LMR' if at least one MRSA isolate was LMR and no HMR isolates were identified during the episode. Potential risk factors for HMR and LMR included in the study were patients' age and gender, type of healthcare episode, MRSA genomic type (HA or CA), previous history of MRSA infection and/or colonization, history of admission to hospital in the previous year and London residency. Analysis of patients' first healthcare episode, restricted to inpatient stays, was also used to investigate differences in level of phenotypic resistance across participant hospitals.
Univariate logistic regression analysis of deduplicated unique-patient isolates was used to investigate whether genotypic and/or phenotypic mupirocin resistance is dependent on the MRSA MLST. The analyses included all isolates (including those from follow-up healthcare episodes) for which complete phenotypic and genotypic mupirocin resistance and MLST data were available. For each patient, consecutive isolates showing identical MRSA MLST, and mupirocin resistance phenotypic and genotypic profile, were assumed to be the same and were deduplicated accordingly for analysis.
The sensitivity, specificity, accuracy, positive and negative predictive values and area under the curve were calculated to examine the reliability of genetic markers to discriminate phenotypic mupirocin resistance. Due to the limited number of isolates, the reliability of genetic markers across MRSA MLSTs was not examined. All analyses and summary statistics were conducted in R-3.1.1 statistical software. 34 
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Results
Analysis of risk factors for phenotypic mupirocin resistance
Some 1523 consecutive isolates from 839 patients presenting with one or multiple healthcare episodes (n ¼ 1096) were retrieved from the microbiology laboratories serving Lambeth, Southwark and Lewisham (Figure 1 ). To avoid pseudoreplication, the analysis was based on the characterization of MRSA isolates from the patients' first healthcare episode, leaving 795 patients' first episodes (1131 isolates) for analysis.
Prevalence of any LMR or HMR amongst patients' first episode (n¼ 795) was 9.69% (95% CI 7.72 -11.96, n¼ 77). LMR was 6.29% (95% CI 4.70 -8.21, n ¼ 50) and HMR 3.40% (95% CI 2.25 -4.90, n ¼ 27). Prevalence of any mupirocin resistance (P ¼ 0.84), LMR (P ¼ 0.79) or HMR (P ¼ 0.74) amongst first inpatient episodes (n¼ 419) was not different across two trusts and one general district hospital included in the study. Only four episodes had combined LMR and HMR and were classified as HMR.
Risk factors for LMR or HMR combined or for LMR or HMR individually are shown in Table 1 Relationship between genotypic and phenotypic mupirocin resistance A total of 665 deduplicated unique-patient MRSA isolates (from 663 episodes and 648 patients), with complete data for MLSTs and genotypic and phenotypic mupirocin resistance, were available for analysis (Figure 1 ). The prevalence of the V588F chromosomal mutation (conferring LMR) was 8.42% (95% CI 6.42-10.80, n¼56) and the prevalence of mupA (conferring HMR) was 3.01% (95% CI 1.85-4.61, n¼20). mupB and V631F mutations were not identified in any isolate. The prevalence of any phenotypic resistance (LMR and HMR combined), phenotypic HMR and LMR in the subset of isolates for which genotypic data were available was similar to that reported by episode {any [9.32% (95% CI 7. Statistical measures of classification performance to examine the reliability of mupA in identifying HMR were based on all 665 deduplicated isolates, whereas the performance of V588F to discriminate LMR excluded 14/665 isolates with combined V588F and mupA carriage (n¼ 651; Table 2 ). The sensitivity of V588F carriage to predict LMR was 67.50% (95% CI 52.50 -82.50) and the specificity was 97.55% (95% CI 96. 24 -98.69 The relationship between carriage of genetic markers and phenotypic resistance by MRSA MLST is summarized in Figure 2 .
Genome sequence data of all mupA-positive isolates (n¼ 23), including same-patient consecutive isolates and isolates with incomplete genetic data, were compared with the pPR9 mupApositive reference plasmid (GU237136) to investigate lack of HMR in 8/23 isolates carrying mupA. This identified mutations in or near mupA likely to result in loss of function in mupA-positive Hughes et al.
isolates that failed to express HMR, but not in those with the HMR phenotype (Table 3 ). Four isolates from three patients had an INDEL (insertion or deletion of DNA bases) of the internal homopolymeric tract resulting in a frameshift and loss of functionality. Three isolates from two patients had a WT mupA, but had significant genetic loss to the upstream gene (p2) that may have resulted in loss of the mupA operon promoter. One susceptible isolate appeared to have a fully functional mupA operon, but had a non-synonymous SNP within mupA.
Genotypic and phenotypic mupirocin resistance and MRSA MLST
Marked differences in carriage of genotypic markers and phenotypic resistance were observed across MRSA MLSTs. ST8 and ST36 were each in excess of 7, 2 and 16 times more likely to exhibit any resistance, LMR or HMR, respectively, than the most commonly identified endemic MLST (ST22) and other sporadic MLSTs. ST8 and ST36 were .10 and .70 times more likely to carry V588F mutation and mupA, respectively, than ST22 and sporadic MLSTs. No HMR or mupA carriage was detected in the closely related ST239 and ST241, but the odds of LMR and V588F carriage in these MLSTs was .20-fold that in ST22 and sporadic MLSTs. See Tables 4 and 5 .
Discussion
This study evaluated phenotypic LMR and HMR and carriage of genotypic markers of resistance in a large series of contemporaneously collected hospital and community MRSA isolates from across three London boroughs and found significant heterogeneity across MRSA clones. Mupirocin use at each trust and hospital during the study period equated to between one and three tubes of mupirocin per admitted colonized MRSA patient and was consistent with adherence to the 'screen and treat' decolonization guidelines, 24 given that the vast majority of nasal mupirocin prescribed is used for MRSA decolonization. In this context, ,10% of patients across the three boroughs had MRSA isolates phenotypically either LMR or HMR with the prevalence of LMR (6%) higher than HMR (3%). Previous studies have more often reported that prevalence of LMR is higher, 13, 14 although one study has reported the reverse. 12 The prevalence of LMR and HMR reported elsewhere is variable, ranging from virtually none to almost 20% for LMR and none to 10% for HMR. 12 -15 Previous studies have generally shown a high concordance between the carriage of mupA and HMR 15, 18, 22, 35 and one study has demonstrated a high concordance between LMR and the presence of the V588F mutation. 36 In this study, carriage of mupirocin resistance genetic determinants had a high specificity (.97%) and area under the curve (.83%) to discriminate phenotypic resistance, suggesting very good diagnostic accuracy. Despite these findings, the correlation between genetic markers and phenotype was imperfect and uncertainty around the sensitivity (95% CI 52.50% -94.44%) precluded us from reporting a conclusive point estimate. Genomic analysis of discordant isolates identified mutations in or near mupA as a likely explanation for loss of HMR, although a single mupA SNP in one susceptible isolate may not have caused loss of function alone. Moreover, four mupA-positive isolates that failed to express HMR had an INDEL MRSA clonal variation in mupirocin resistance 3195 JAC of the internal homopolymeric tract that allows for subsequent slipped-strand mispairing mutation to restore functionality, supporting observations that HMR might be phase variable or transient. 37 Gene carriage, therefore, does not invariably translate into expression of resistance 37, 38 and this limits the use of genetic markers to infer phenotype unless detailed genetic analysis is undertaken. Discordance between LMR and V588F and an explanation for HMR in four mupA-negative isolates is presently lacking and the focus of further research.
The main finding from this study, with significant clinical implications, was the high heterogeneity in the distribution of phenotypic and genotypic markers of resistance across MRSA clones. Phenotypic HMR and mupA were predominantly found in ST8 and ST36, whilst phenotypic LMR and V588F were predominantly in ST239/241 as well as ST8 and ST36. HMR and LMR were low (,4%) in the current dominant UK MRSA clone ST22 and community/sporadic MRSA isolates. To our knowledge, this is the first study to report clonal variation in LMR and V588F mutation from clinical isolates. This supports a recent in vitro study, which suggests that mutations conferring LMR may be more readily inducible in some clones. 39 Clonal variation in HMR has been shown previously. 16 -18 A plausible explanation for the latter may be that particular MRSA clones are more receptive to conjugation with CoNS 40 that commonly carry mupA and which may act as a reservoir for transmission into S. aureus. 41 An explanation for clonal variation in LMR and V588F is presently lacking.
We hypothesize that local variation in dominant MRSA clones may, at least in part, explain why increasing mupirocin resistance associated with intensive mupirocin use has only been reported in some studies. 1, 36, 42 At least for the case of HMR, there is evidence that a difference in resistance phenotype in the dominant UK clones ST22 and ST36 has existed for many years and at GSTT it pre-dates the introduction of intensive decolonization as part of the successful 'screen and treat' infection control campaign that began in 2004. Between 1999 and 2004, ST36 caused 50.0% of 498 MRSA bloodstream infections of which 40.1% were HMR, whereas ST22 comprised 29.5%, but none was HMR (data extracted from dataset used by Miller et al. 33 ). Subsequently, Lack of selection for mupirocin resistance at GSTT is likely to be multifactorial, with clonal composition playing a pivotal role. Firstly, there may be an intrinsic lower propensity of clones such as ST22 to acquire resistance. Secondly, resistant clones may carry a fitness cost making them less transmissible than susceptible clones. Evidence for the latter has been reported in a recent companion study 43 and may help explain the particularly rapid decline of ST36 over the past 10 years in the context of improving infection control practice. 44 Thirdly, a conservative approach to MRSA control-where mupirocin prescription is targeted to MRSA carriers only-may not provide significant selection of resistance. Indeed, simulation studies show that prevalence of resistance is expected to remain stable under 'screen and treat' guidelines whilst it is predicted to increase under 'universal' use. 43 Our study has a number of strengths. We determined phenotypic and genotypic resistance for a large collection of consecutive MRSA isolates from adjacent laboratories covering five different London hospitals and their adjacent community. Also, we analysed anonymized patient-level data in order to derive risk factors for LMR and HMR. These findings will prove useful to inform the development of mupirocin resistance transmission models to evaluate the threat that may arise from increasing mupirocin usage. The limitations are that we only evaluated known mechanisms for LMR and HMR and, although we had access to detailed clinical information, we did not have data on use of mupirocin for individual patients.
In summary, mupirocin resistance varies significantly by clone, implying that changes in clonal epidemiology may have an important role in determining the prevalence of resistance in conjunction with selection due to mupirocin use. Low levels of resistance (,10%) across central/south-east London after an extended period of decolonization linked with a successful UK MRSA control programme may in part be explained by the MRSA clonal variation in mupirocin resistance MRSA clonal population structure and specifically by ST22 being the dominant clone. We conclude that mupirocin use alone is not sufficient to predict resistance trends and that determining the local population of MRSA MLSTs and monitoring changes in the population structure may be a useful way of guiding mupirocin usage policies.
